At Oxford StemTech, we have developed the novel ReproPlex™ platform that drastically reduces the cost and enables large scale parallel reprogramming to produce induced pluripotent stem cell (iPSCs) from 10-100s of donors simultaneously, without compromising quality. The production of stem cells from large numbers of patients can then enable precision medicine development and population level cellular studies.

We can generate iPSCs for you in a fast, highly efficient and cost-effective manner using Oxford StemTech’s innovative reprogramming technology, the ReproPlex™ platform. We can generate iPSCs for you with minimum blood volume of 2ml and deliver the iPSCs with the complete quality control report on time. We can also do this from skin biopsy and keratinocytes.

Additionally, we can contribute to your mission to better understand the disease, discover novel targets and conduct in vitro clinical trials to get medicines that work into the clinic.